

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. **(Previously Pending)** A compound selected from the group consisting of:  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine [7];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-methoxy-phenyl)-amine [8];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-iodo-phenyl)-amine [11];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-fluoro-phenyl)-amine [12];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-bromo-phenyl)-amine [17];  
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56];  
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58];  
2-{5-[2-(4-Fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-ylamino}-ethanol [59];  
2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60];  
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-nitro-phenyl)-amine [63];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(phenyl)-amine [64]; and  
4-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-benzenesulfonic acid [65]; or a pharmaceutically acceptable salt thereof.

2. **(Previously Presented)** A compound according to claim 1, selected from the group consisting of:

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];  
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
methanesulfonamide [56];  
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol  
[58];  
2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
acetamide [60]; and  
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-  
acetamide [61], or a pharmaceutically acceptable salt thereof.

**3. (Previously Presented)** A compound according to claim 2, selected from the group consisting of:

2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
acetamide [60]; and  
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-  
acetamide [61], or a pharmaceutically acceptable salt thereof.

**4. (Previously Presented)** A compound according to claim 1, selected from the following:

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];  
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
methanesulfonamide [56]; and  
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol  
[58] or a pharmaceutically acceptable salt thereof.

**5. (Previously Presented)** The compound of claim 4, wherein said compound is 2-{4-Methyl-5-[2-(3-nitro-phenyl amino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58] or a pharmaceutically acceptable salt thereof.

Claims 6-9 (**Cancelled**).

10. **(Previously Presented)** A compound according to claim 1 which is selected from the group consisting of:

[4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];

*N*-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56]; and

2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58]; or a pharmaceutically acceptable salt thereof.

11. **(Previously Presented)** A compound according to claim 1 which is [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1]; or a pharmaceutically acceptable salt thereof.

12. **(Previously Presented)** A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

13. **(Original)** A pharmaceutical composition according to claim 12 which further comprises one or more other anticancer agents.

14. **(Currently Amended)** A method for treating a ~~CDK-sensitive or CDK-dependent~~ proliferative disorder in a subject, comprising administering one or more compound of claim 1, or a pharmaceutically acceptable salt thereof, to a subject, such that the subject is treated for a proliferative disorder, wherein said proliferative disorder is selected from the group consisting of bone cancer, breast cancer, cervical cancer, colon cancer, stomach cancer, leiomyosarcoma, leukaemia, lung cancer, brain cancer, prostate cancer, skin cancer, and uterine cancer.

15. **(Currently Amended)** The method of claim 14, wherein the proliferative disorder is ~~cancer or~~ leukaemia.

Claims 16-18 **(Cancelled)**.

19. **(Previously Presented)** The method of claim 14, wherein said compound is administered in combination with one or more other anticancer agents.

20. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is lung cancer.
21. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is colon cancer.
22. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is bone cancer.
23. **(New)** The method of claim 22, wherein said bone cancer is bone osteosarcoma or osteogenic sarcoma.
24. **(New)** The method of claim 14, wherein said proliferative disorder is breast cancer.
25. **(New)** The method of claim 14, wherein said proliferative disorder is cervical cancer.
26. **(New)** The method of claim 14, wherein said stomach cancer is gastric adenocarcinoma.
27. **(New)** The method of claim 14, wherein said proliferative disorder is leiomyosarcoma.
28. **(New)** The method of claim 15, wherein said leukaemia is chronic myelogenous leukaemia or promyelocytic leukaemia.
29. **(New)** The method of claim 14, wherein said brain cancer is neuroblastoma.
30. **(New)** The method of claim 14, wherein said proliferative disorder is prostate cancer.
31. **(New)** The method of claim 14, wherein said proliferative disorder is skin cancer.

32. (New) The method of claim 14, wherein said proliferative disorder is uterine cancer.